Documente Academic
Documente Profesional
Documente Cultură
to tackle drug-resistant
superbugs
_____________________________
Q+A
1. What has led to the rise in drug resistant superbugs?
2. Why are big pharmaceutical companies reluctant to develop
new antibiotics?
3. What is the estimated number of fatalities by 2050? Where are
these deaths most likely to occur?
4. Which are more important areas of research, life-extending
drugs or lifesaving antibiotics?
5. Do you worry about the prospect of a pandemic striking Japan?
6. Should governments stockpile medicine to prepare for such an
VOCABULARY: eventuality or is this a huge waste of money?
__________________________________________________________
1. rule of thumb DEFINITIONS:
10 million The number of people who will die every year due to
AMR by 2050.
90% of these deaths will be in Asia and Africa.
$100 trillion, the estimated total GDP that will be lost globally by
2050 if AMR isnt tackled.
$2bn, the size of the fund ONeill says should be established to
fund AMR research.
$2-3bn, the reward ONeill suggests drug companies are paid for
launching a new antibiotic on a not-for-profit basis.
__________________________________________________________
Matt Cooper, a medical chemist at the University of Queensland,
Australia, puffs out his cheeks and scratches his head. Hes trying
to explain why the _____________ for new antibiotics is quite so